Anavex Life Sciences Corp.
http://www.anavex.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Anavex Life Sciences Corp.
Anavex Reveals Positive Phase III Data In Rett Syndrome But A Surprise Endpoint
The endpoint used in the AVATAR trial was different than the one investors had expected; management said the change was made to satisfy the US FDA.
Acadia’s Trofinetide Shows Efficacy In Rett Syndrome, But Safety Looks Shaky
Trofinetide could be the first approved drug for Rett patients after hitting both co-primary endpoints in a Phase III trial, but high rates of diarrhea and vomiting raise questions.
Aduhelm Approval Boosts Other Alzheimer’s Drug Developers
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
Start-Up News
Noteworthy news from medtech start-ups. This month we profile Ibris, which is developing prognostics to identify breast cancer patients in need of chemotherapy, and Delphinus Medical Technologies, whose platform enables 3-D full breast ultrasound.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Anavex Australia Pty Ltd.